Skip to main content
  • Loading metrics

Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling

  • Siew Pheng Lim ,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Christian Guy Noble,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Cheah Chen Seh,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Tingjin Sherryl Soh,

    Affiliations Novartis Institute for Tropical Diseases, Singapore, School of Biological Sciences, Nanyang Technological University, Singapore

  • Abbas El Sahili,

    Affiliation School of Biological Sciences, Nanyang Technological University, Singapore

  • Grace Kar Yarn Chan,

    Affiliation School of Biological Sciences, Nanyang Technological University, Singapore

  • Julien Lescar,

    Affiliations School of Biological Sciences, Nanyang Technological University, Singapore, UPMC UMRS CR7—CNRS ERL 8255-INSERM U1135 Centre d’Immunologie et des Maladies Infectieuses, Centre Hospitalier Universitaire Pitié-Salpêtrière, Faculté de Médecine Pierre et Marie Curie, Paris, France

  • Rishi Arora,

    Affiliation Novartis Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

  • Timothy Benson,

    Affiliation Novartis Institute for Biomedical Research, Cambridge, Massachusetts, United States of America

  • Shahul Nilar,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Ujjini Manjunatha,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Kah Fei Wan,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Hongping Dong,

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Xuping Xie,

    Current address: Department of Biochemistry & Molecular Biology, Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX 77555, USA.

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • Pei-Yong Shi,

    Current address: Department of Biochemistry & Molecular Biology, Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX 77555, USA.

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  •  [ ... ],
  • Fumiaki Yokokawa

    Affiliation Novartis Institute for Tropical Diseases, Singapore

  • [ view all ]
  • [ view less ]


Flaviviruses comprise major emerging pathogens such as dengue virus (DENV) or Zika virus (ZIKV). The flavivirus RNA genome is replicated by the RNA-dependent-RNA polymerase (RdRp) domain of non-structural protein 5 (NS5). This essential enzymatic activity renders the RdRp attractive for antiviral therapy. NS5 synthesizes viral RNA via a “de novo” initiation mechanism. Crystal structures of the flavivirus RdRp revealed a “closed” conformation reminiscent of a pre-initiation state, with a well ordered priming loop that extrudes from the thumb subdomain into the dsRNA exit tunnel, close to the “GDD” active site. To-date, no allosteric pockets have been identified for the RdRp, and compound screening campaigns did not yield suitable drug candidates. Using fragment-based screening via X-ray crystallography, we found a fragment that bound to a pocket of the apo-DENV RdRp close to its active site (termed “N pocket”). Structure-guided improvements yielded DENV pan-serotype inhibitors of the RdRp de novo initiation activity with nano-molar potency that also impeded elongation activity at micro-molar concentrations. Inhibitors exhibited mixed inhibition kinetics with respect to competition with the RNA or GTP substrate. The best compounds have EC50 values of 1–2 μM against all four DENV serotypes in cell culture assays. Genome-sequencing of compound-resistant DENV replicons, identified amino acid changes that mapped to the N pocket. Since inhibitors bind at the thumb/palm interface of the RdRp, this class of compounds is proposed to hinder RdRp conformational changes during its transition from initiation to elongation. This is the first report of a class of pan-serotype and cell-active DENV RdRp inhibitors. Given the evolutionary conservation of residues lining the N pocket, these molecules offer insights to treat other serious conditions caused by flaviviruses.

Author Summary

Dengue virus (DENV) is the world’s most prevalent mosquito-borne viral disease and nearly 40% of the world’s population is at risk of infection. Currently, no specific drugs are available to treat dengue or other flaviviral diseases. DENV NS5 is a large protein of 900 amino acids composed of two domains with key enzymatic activities for viral RNA replication in the host cell and constitutes a prime target for the design of anti-viral inhibitors. We performed a fragment-based screening by X-ray crystallography targeting the DENV NS5 polymerase and identified an allosteric binding pocket at the base of the thumb subdomain close to the enzyme active site. Potent inhibitors active in both DENV polymerase biochemical and cell-based assays were developed through structure-guided design. Resistant virus replicons grown in the presence of the inhibitor, harbored amino acid changes that mapped to the compound binding site. The proposed mode of action for this class of inhibitors is by impeding RdRp protein conformational changes during the transition from initiation to elongation phase of enzyme activity.


Several flaviviruses, such as DENV, Japanese Encephalitis virus (JEV), West Nile virus (WNV), Yellow Fever virus (YFV) or Tick-borne encephalitis virus (TBEV) are major human pathogens, whilst Zika (ZIKV) is an emerging flavivirus of global significance causing severe neurological conditions in infected adults and newborn babies, most likely by mother-to-child transmission [1]. The mosquito-borne DENV causes widespread epidemics in over 100 countries, with ∼390 million infections each year [2]. Infection by any of the four DENV serotypes can lead to several outcomes, ranging from asymptomatic infection, dengue fever, to dengue hemorrhagic fever and dengue shock syndrome. After several decades of efforts, the first vaccine was recently licensed for use, but confers only partial cross protection for the four DENV serotypes [3, 4]. No antivirals have been approved to treat dengue or other flaviviral diseases [5].

Flavivirus RNA replication occurs in host cells on endoplasmic reticulum-derived membranes within a multi-protein replication complex (RC) consisting of viral NS proteins and host cofactors [68]. Comprising 900 amino acid residues, NS5 is the largest and most conserved protein component of the flavivirus RC. Its N-terminal domain (residues 1–265 in DENV3) is an S-adenosyl-L-methionine (SAM)-dependent methyltransferase (MTase) that methylates the viral RNA genome cap [915]. A guanylyltransferase activity was also proposed for the N-terminal domain of NS5 [16, 17]. Its C-terminal RdRp domain (residues 267–900) synthesizes the viral genomic RNA [1822]. A potentially flexible linker region that connects the two catalytic domains of NS5 regulates RdRp activities and virus replication by modulating MTase-RdRp interactions [2325]. In addition to its enzymatic functions, NS5 inhibits host interferon-mediated signaling by promoting degradation of STAT2 [26]. In DENV, NS5 localizes to the nucleus of infected cells in a serotype-dependent manner that modulates host processes [27].

Following DENV infection, the RdRp synthesizes viral RNA in the absence of a primer strand, via a de novo initiation mechanism, in which the (+) strand viral RNA template is transcribed into a complementary RNA strand of (-) polarity [18, 19]. This duplex in turn serves as a template for synthesis of additional RNA strands of (+) polarity that either act as mRNA for protein translation or are packaged into virions. DENV RdRp possesses a right hand-like architecture conserved across different polymerase families [21, 22, 25], with three subdomains termed ‘‘fingers”, ‘‘palm” and ‘‘thumb”. Within these subdomains, seven conserved amino-acid sequence motifs play key roles for binding RNA, NTPs and metal-ions and for catalysis [28, 29]. Structures of the apo-DENV RdRp were found to adopt a “closed” pre-initiation state conformation, with a well-ordered priming loop projecting into a narrow RNA binding tunnel. Disordered peptide segments were observed in motifs F, G and at the C-terminal end [21, 22, 25].

The importance of NS5 for viral replication makes it an ideal target for developing inhibitors to treat diseases caused by flaviviruses [3032]. Although several high-throughput screening campaigns have been performed, only a few DENV RdRp non-nucleoside inhibitors have been described [3336]. From these latter efforts, we previously identified two compounds that bind to the RNA tunnel but did not succeed in improving their lead-like properties [34, 35]. Here, using fragment-based screening via X-ray crystallography targeting the apo-DENV RdRp, we identified a fragment that bound to a pocket located in the thumb subdomain, close to the enzyme active site, which we term as the “N pocket” [37, 38]. Using a structure-guided approach that combines biochemical, biophysical and cell-based assays, we designed potent inhibitors that bound to this allosteric site, and inhibited DENV1-4 viral replication across various cell-based assays. Resistant DENV replicons with amino acid changes in the “N” pocket were raised with two compounds, confirming that the NS5 polymerase was the specific target for this class of inhibitors in DENV infected cells. To our knowledge, this is the first report of a Flavivirus RdRp allosteric pocket and the successful use of structure-guided approach for designing potent inhibitors targeting NS5. This work has major implications for the design of much-needed flavivirus anti-viral inhibitors.


Structure-guided design of a novel chemical scaffold that binds to the DENV RdRp N pocket

Following fragment-based screening using X-ray crystallography, we identified 3, a bi-phenyl acetic acid fragment, that bound to a pocket in the DENV3 RdRp thumb subdomain (IC50≈ 734 μM; Fig 1 and Table 1; 37). Iterative rounds of structure-guided design led to compounds that inhibited both DENV polymerase activity and viral replication in cells (Fig 1 and Table 1; Fig 1A and 1B in S1 Text). Firstly, switching the distal unsubstituted phenyl ring in 3, with a thiophene ring (3i) improved compound potency by >12-fold in DENV1-4 polymerase de novo initiation (dnI) enzyme assays [38, 39]. Substitution of the methoxyl group on the outer phenyl ring with a second acid moiety increased potency in DENV-1 and -3 (compare 3i and 11). Replacement of the chloro-substituent on the thiophene ring in 11, with a propargyl alcohol, markedly increased compound inhibitory property. Compound 15, which bears this moiety, was >16-fold more active across DENV1-4 enzymes. Whilst subsequent derivatives, exemplified by compound 15, displayed low nano-molar potencies across DENV1-4 dnI polymerase assays, they failed to inhibit DENV replication in cells. This is probably due to unfavorable physicochemical properties that limited their cell permeability (likely due to the presence of bis-carboxylic acid groups in 15).

Fig 1. Structures of N-pocket inhibitors.

N-pocket inhibitors listed in order of increasing potency in DENV enzyme and replicon cell-based assays. Compound 3 is the original hit identified from the fragment-based screening [37]. Compounds 3i to 29i were synthesized through rational design [38] following compound testing in DENV4 FL NS5 dnI assay, SPR analyses and X-ray co-crystallography.

Table 1. Inhibitory properties of DENV polymerase N-pocket compounds.

Successive design strategies produced compounds with acyl-sulfonamide derivatives (replacing the charged acid groups with the acyl-sulfonamide bio-isosteres increases lipophilicity) with EC50 ≥ 2 μM, in a HuH-7 DENV2 replicon cell-based assay (Fig 1 and Table 1; Fig 1B in S1 Text). The most active compounds in this series, 29 and 29i, bear the 8-quinolinol moiety, and demonstrated IC50 values ranging from 0.013 to 0.074 μM across DENV1-4 polymerase, with EC50 value of ~2 μM in the DENV2 replicon cell-based assay (Table 1).

Kinetic studies of DENV RdRp inhibition

To better understand the inhibition mode of this class of compounds, order-of-reagent addition experiments were performed using the DENV dnI FAPA assay (Table 2). The standard assay format involved compounds exposed to enzyme alone followed by reaction initiations with ssRNA template and NTPs [39]. In the first experiments, compounds 15, 27 and 29 were exposed to pre-formed enzyme-ssRNA complexes, followed by reaction initiation with NTPs. IC50 values generated for 15 and 27 were similar to the standard assay format, suggesting that these compounds do not discriminate between the apo-enzyme and the polymerase bound to ssRNA. Compound 29, showed about 3-fold reduction in potency. Next, compounds were exposed to elongated enzyme-dsRNA complexes, in which the active site was occupied by the ssRNA template and newly synthesized short RNA products AGAA or AGAACC. Resulting compound inhibitory potencies dropped by 8–15 fold. The change was most pronounced in compound 29 (10–15 fold decline). These findings imply that during transition from initiation to the elongation complex, to accommodate the growing dsRNA product, the N-pocket underwent conformational changes, leading to decrease in compound binding affinities. To verify these findings, we tested the compounds in the DENV elongation FAPA assay by exposing the compounds to enzyme alone, followed by reaction initiation with duplex hetero-polymeric RNA templates [25]. Similarly, compound potencies were markedly reduced. Their IC50 values were 10–23 folds weaker than in the standard dnI assay, with 27 showing the greatest change in potency. Nevertheless, compound 29 retained potent inhibitory activity, with IC50 values ranging from 0.023–0.427 μM across the different enzyme assays and formats. Control 3’dGTP showed similar IC50 values in order-of-addition reagent experiments and in the DENV elongation FAPA assay.

Table 2. Inhibitory and binding properties of DENV polymerase N-pocket compounds.

We proceeded to characterize the inhibition kinetics of compounds 15 and 29, in the dnI FAPA assay, using 3’dGTP, as a control (Fig 2; Fig 2 in S1 Text). As expected, kinetics studies using Lineweaver-Burk plots showed that 3’dGTP was a competitive inhibitor of GTP, but a non-competitive inhibitor of the viral RNA substrate. Both 15 and 29 exhibited uncompetitive inhibition profiles with respect to the viral ssRNA template. Results from kinetic competition experiments with GTP were more complex. Lineweaver-Burk plots of 15 and 29 were indicative of uncompetitive inhibition. However, at high GTP concentrations, a non-competitive mode of inhibition by these compounds was apparent. Both de novo initiation and elongation activities occur in the DENV polymerase dnI assay. For the rate-limiting de novo RNA synthesis step, the Km for GTP was found to be >20 μM [19], whilst a low Km value (0.2–0.4 μM; 18, 39) was reported for the elongation phase. It is possible that the mixed inhibition profiles for both compounds, reflect differential effects on the dnI and elongation phases of the enzyme activities. Indeed, the significantly weaker inhibitory capabilities of these compounds in the DENV elongation assay support this hypothesis. Furthermore, both compounds are not true un- or non-competitive inhibitors as they are also able to bind to the apo-enzyme with high affinity (see below).

Fig 2. Enzyme inhibition kinetics of N-pocket compounds against DENV polymerase.

DENV4 FL NS5 dnI FAPA assays [39] were performed in increasing concentrations of 3’dGTP control (A, B), N-pocket inhibitor, 15 (C, D) or 29 (E, F) with 0–500 nM RNA (A, C, E) or 0–50 μM GTP (B, D, F) to determine mechanisms of inhibition with respect to either substrates. Representative Lineweaver-Burk plots were derived from non-linear regression curve fitting using GraphPad Prism software. Control inhibitor 3’dGTP shows competitive inhibition with respect to GTP and non-competitive inhibition, with respect to RNA substrate.

Crystal structures of DENV RdRp bound to compounds 27 and 29

DENV3 RdRp co-crystal structures with 27 and 29 solved to 2.45 Å and 1.88 Å resolution respectively (Table 3), show that the compounds occupy about 60% of the N-pocket volume and establish multiple polar contacts with several neighboring amino acid residues (Fig 3). The RdRp retains essentially the same structure as in its unbound form [21, 22] with RMSD of 0.25 Å for 612 superimposed α-carbon atoms (the RMSD is 0.18 Å between the two complexes). The compound binding mode is reminiscent of other closely-related analogs [38] with complete overlap in the positions of their most buried moieties: the thiophene ring and propargyl alcohol, whilst acyl-sulfonamide and the solvent-exposed ring: 8-quinolinol ring in 29 and methoxy-substituted phenol ring in 27, adopt different orientations. The sulfur of the thiophene ring makes a non-covalent interaction with the side-chain hydroxyl of S796, whilst the terminal propargyl alcohol arm extends deeply into a tunnel lined by residues W803, M761, and M765. Its terminal hydroxyl group forms H-bond interactions with the backbone amide of H800 and the side-chain of Q802, and displaced a single buried water molecule present in the RdRp apo structure [21, 22]. In addition, the acyl-sulfonamide carbonyl moiety forms hydrogen bonds with the side chain of T794, and additionally in 27, with the backbone amide of W795 via an intercalated water molecule. Co-crystallization of compounds 27 and 29 with DENV3 FL NS5 led to the same binding mode as observed for the polymerase domain (Fig 3 and Table 1 in S1 Text). Soaking of compound 27 in crystals of DENV2 (NGC strain) RdRp domain also generated the same binding mode, with the OH- moiety of the propargyl arm forming similar hydrogen bonds with residues K800 (backbone N) and E802 (carboxylic acid side chain), as H800 and Q802 in the DENV3 RdRp-29 co-crystal structure (Fig 3D and 3E).

Fig 3. Crystal structure and binding of compounds 27 and 29 to DENV3 RdRp.

(A) Overview of DENV3 RdRp bound to compound 29 (boxed), displayed as ribbons with the palm subdomain in red, finger subdomain in cyan, thumb subdomain in olive and compound 29 shown as yellow sticks. The lower left panel shows a view from “the bottom of the RdRp structure” with respect to the usual “front view”. (B) Close-up view of compound 29 binding site in the N-pocket. A difference electron density map with Fourier coefficients Fo-Fc where the compound was omitted from the phase calculation is overlaid and contoured at 3 σ level. (C) Residues lining the N-pocket for 29 are shown as cyan sticks with the compound shown as yellow sticks. Individual residues are labelled according to their numbering in the DENV3 polymerase and H-bond interactions are indicated with dashed lines. Two-dimensional ligand-interaction maps of co-crystals of DENV3 (D) and DENV2 (E) RdRp domains, bound with compounds 29 and 27, respectively, were generated using Molecular Operating Environment. Polar residues are colored light purple, charged residues have an additional blue ring and lipophilic residues are green. The degree of solvent exposure is shown by the blue halos. H-bond interactions to the amino acid side chain or main chain are shown as dashed green or blue arrows respectively, pointing towards the H-bond acceptor. Water-mediated contacts are shown as gold dashed lines. (F) Binding of 27 to the DENV4 RdRp using surface plasmon resonance in a two-fold serial dilution from a top concentration of 2.5 μM. Raw data (coloured lines) was globally fitted to a simple 1:1 binding model (black lines). (G) Multiple alignment of amino acid residues of compound binding pocket (coloured in red and green) across different members of the Flavivirus family derived from Clustal Omega program [42]. Phylogenetic tree representing their relatedness is shown in Fig 4 in S1 Text. Strictly conserved amino acids are marked with an asterisk below the sequences (and in red font), semi-conserved residues with a colon (and in green font) whilst poorly conserved residues are marked with a dot.

Table 3. Data collection and refinement statistics of DENV3 RdRp co-crystals.

The 10-fold higher binding affinity of 29 over 27 for DENV RdRp, observed in SPR analyses (Table 2) can be accounted for by formation of three additional hydrogen-bonds between the 8-quinolinol ring of 29 with the side chain of R729 (these favorable contacts are absent in 27 with the corresponding ring pointing towards the solvent away from R729). Thermo-denaturation studies using recombinant DENV FL NS5, RdRp and FL NS5 from DENV-replicon lysates further corroborated these findings. In these experiments, 29 consistently stabilized DENV polymerase better than 27, leading to 2.5–6 °C better increase in protein melting temperatures compared to 27 (Table 2; Fig 5 in S1 Text). Compound binding fits to a simple 1:1 binding model in SPR analyses, correlating well with the X-ray crystallography data (Fig 3F).

Residues lining the N-pocket play an important role in de novo initiation activity

To assess the functional relevance of the N-pocket for DENV polymerase activity, we targeted RdRp residues interacting with 27 or 29 as well as residues lining the N-pocket (Fig 3G), and measured both de novo initiation (dnI) and elongation activities of the corresponding RdRp Ala mutants. All mutant proteins studied have similar melting temperatures as WT, indicating that stabilities of the protein structures were not compromised by the alanine substitutions (Table 4). Overall, the results indicate that N pocket residues play an important role in DENV polymerase dnI and have less impact on elongation. This is particularly evident in the S710A and R737A mutants, where dnI activities were substantially reduced, to 26.6 and 0%, respectively, compared to WT, whilst retaining about 72% elongation activity. Both residues are completely conserved across the Flavivirus family (Fig 3G). Thus, the N pocket conformation observed in the inhibitor-bound crystal structures is likely to correspond to the structural state adopted by the DENV RdRp during dnI [21, 22].

Table 4. Alanine substitutions of N-pocket amino acid residues that interact with compounds 27 and 29.

To further validate the mode of binding of this class of inhibitors in the N-pocket, we performed inhibition assays using mutant proteins S796A and W803A, both of which retain about 66% de novo initiation activity (Table 5). Residue S796 interacts with the sulfur-atom in the thiophene ring whilst W803A lines the propargyl alcohol tunnel. As a control, we used 3’dGTP, which retained the same IC50 when tested on the mutant enzymes. All four compounds exhibited more than 10 fold increases in their IC50 values, when assayed with S796A and W803A mutant RdRp. Compounds 27 and 29 gave the greatest IC50 shifts when tested with mutant W803A (107- and 70-fold respectively). In agreement with the X-ray crystallography data, 11, which bears a–Cl substituent instead of the extended propargyl alcohol arm on the thiophene ring, showed only 9–10 fold increase. Taken together these biochemical studies substantiate the binding modes observed in the X-ray co-crystal structures.

Table 5. Effect of alanine mutations of pocket amino acid residues on compound inhibitory properties on DENV4 polymerase de novo initiation activity.

Reverse genetics studies of the DENV polymerase N-pocket

We next investigated the biological effects of alanine mutation of residues S710, R729, R737, Y766, T794, S796, H800, Q803 or W803 in the context of a DENV4 replicon (Fig 4, Table 4). Following electroporation into BHK-21 cells, WT replicon replicated robustly, generating renilla luciferase signals that were 422-fold above background levels (measured at 24 hr post-electroporation). Its growth rate subsequently plateaued at 48 hr (605-fold above background). Thereafter, luciferase levels dropped 25-fold at 72 hr post-transfection. In comparison, mutant replicons bearing R729A or R737A substitutions were non-replicative, a result that is in good agreement with their poor in vitro NS5 polymerase activity profiles (Table 4). R729A RdRp exhibited about 30–40% of both dnI and elongation activities whilst dnI activity of R737A was completely abolished. Mutant replicons S710A, Y766A, and W803A were also non-replicative, despite showing 27–98% de novo initiation and elongation activities in vitro. Mutant replicons H800A and Q802A were poorly replicative, although their polymerase activities were only moderately decreased in the enzyme assays. In contrast, mutant replicons with T794A, S796A with similar reductions in polymerase activities, were more replicative, and continued to expand during the three-day incubation period. At 24 hr post-electroporation, their luciferase activities were respectively 838- and 456-folds poorer than WT replicon activity. By day 3, the difference had narrowed to 4.5- and 5.1-fold, respectively, lower than WT replicon activity. The reason for the difference in the replicative profiles of these latter four DENV4 mutants is uncertain. It is possible that within the context of the replicative complex, mutating these residues produced subtle differential effects on NS5 polymerase activity that translate in large variation in terms of virus replicon fitness.

Fig 4. Growth kinetics of WT and N-pocket mutant DENV4 replicons.

In vitro transcribed WT and mutant replicon cDNAs bearing single alanine substitutions in NS5 polymerase N-pocket amino acid residues were electroporated into BHK-21 cells and the levels of cellular renilla luciferase measured over three days using the renilla luciferase assay system (Promega, USA) with a Clarity luminescence microplate reader (BioTek, USA). Amino acid residues denoted DENV3 numbering (see Table 4).

Compounds targeting the N pocket are active in DENV cell-based assays

Using DENV cell-based assays, we next examined the inhibitory properties of four potent compounds in the series (Table 6). Compounds 27, 29 and 29i demonstrated similar EC50 values ranging from 1–5 μM in DENV2 replicon cells from HuH-7, BHK-21 and A549 backgrounds while 26i was slightly less active (EC50 = 12–15 μM). When inhibition studies were performed with clinical isolates of DENV1-4, 27 inhibited all four serotypes with EC50 ~2 μM. Compound 29i was the next most potent compound with EC50 values of 1–6 μM. Despite demonstrating significantly higher potency against DENV1-4 RdRp in the dnI enzymatic assays, 29 displayed relatively lower cellular inhibition (EC50 = 4–13 μM), particularly with DENV-2 and -4 (EC50 = 14.1 μM and 10.2 μM respectively). Similar to the observation with replicon cells, 26i was also the least active against DENV1-4 viruses. All four inhibitors were inactive against HCV replicon and human rhinoviruses (with EC50 values >25 and >50 μM. respectively). No cytotoxicity was observed in five different cell lines tested (EC50 >50 μM).

Table 6. Inhibitory profiles of N-pocket compounds in DENV cell-based assays.

Both 27 and 29i have an extra methoxy moiety on their central phenyl ring compared to 26i and 29. The inhibition results indicate that the additional methoxy group present in the former compounds may be advantageous for inhibiting infectious DENV as they are consistently more active than the cognate analogs devoid of this moiety (26i and 29 respectively). It is possible that this additional substituent allows for the formation of an intra-hydrogen bond with the N-atom of the sulfonamide linker facilitating better cell permeability. Notably, whilst EC50 values of 29i with DENV-1, -3 and -4 were comparable with 27, its DENV2 EC50 value was about two-fold lower.

Resistant DENV2 replicons raised against compound 29 harbor mutations that map to the N-pocket

To confirm that the antiviral activity displayed by this series of compounds was due to the specific inhibition of RdRp, we raised resistant DENV2 EGFP-replicons using compounds 27 and 29 (Table 6). We first propagated DENV2-NGC EGFP replicon cells in 20 μM of 29 (≈1X EC90 value) and increased the compound concentration to 25 μM after 5 weeks. RNA was sequenced from individual colonies of resistant cells that grew in the latter compound concentration, as well as from a mixed population of cells kept in 20 μM of 29 (Fig 5). Two individual 29-resistant replicon clones harbored the same single nucleotide change in NS5 (GAA→GAC), resulting in E802D mutation (note that residue 802 is E in DENV2-NGC and Q in DENV3 used for structure determination). A third clone contained another single nucleotide change in NS5 (CTG→GTG), resulting in L511V mutation. A fourth clone contained a mixed profile in NS5, in the same position, with both the WT nucleotide (G) as well as mutation to C nucleotide present (GTG→G/CTG), giving rise to partial L511V mutation.

Fig 5. NS5 sequence analyses of compound 27- and 29-resistant DENV2 EGFP-replicon cells.

(A, B) DENV2-NGC EGFP-replicon clones 1 and 2 (C1 and C2, respectively) cultured in 25 μM of compound 29 over a period of >5 weeks contained a single nucleotide change in NS5 (GAA→GAC), resulting in mutation of amino acid E802 (wildtype, WT) to D802. (C) Mixed population of DENV2-NGC EGFP-replicon cells cultured in 28 μM of compound 27, of over a period of >6 weeks contained a single partial nucleotide change in NS5 (GAA→GAA/T), resulting in partial E802D mutation. (D) DENV2-NGC EGFP-replicon clone 3 (C3) cultured in 25 μM of compound 29 over a period of >5 weeks contained a single nucleotide change in NS5 (CTG→GTG), resulting in mutation of amino acid L511 (WT) to V511. (E) DENV2 EGFP-replicon clone 4 (C4) cultured in 25 μM of 29 over a period of >5 weeks contained a single partial nucleotide change in the same position (GTG→G/CTG), giving rise to partial L511V mutation. FOR and REV denote the nucleotide sequence information obtained with NS5 forward and reverse sequencing primers, respectively. Arrows denoted position of nucleotide change observed in replicon clones and mixed cell populations.

Similar attempts to raise 27-resistant cells by exposure to high concentrations of 27 (14–20 μM; ≈2X EC90 value) were not successful. We then exposed the DENV2-NGC replicon cells with gradually increasing concentrations of 27 (starting from 1.5 μM; ≈0.5X EC50). After about 6 weeks, cells in 28 μM of 27 propagated robustly, at similar rates to WT replicon cells. Further increases in compound concentrations resulted in cell death and no individual resistant colonies were obtained. RNA was sequenced from a mixed population of replicon cells maintained in 28 μM of 27. A partial E802D mutation profile (GAA→GAA/T) was observed (Fig 5).

The crystal structure of DENV3-RdRp bound to 29 (Fig 3C) shows that the polar side chain of residue Q802 (E802 in DENV2) hydrogens bond with the hydroxyl group of the propargyl alcohol of 29. E802D mutation results in the shortening of the amino acid side-chain by one methyl group and is likely to disrupt this H-bond formation. Residue L511 (in DENV-2 and -3) forms van der Waals interactions with the thiophene ring of 29. In this case, loss of a methyl group in L511V is likely to weaken the interaction with the thiophene ring of the inhibitor. As a result these mutations lower the binding affinity of 29 in the N pocket. These findings thus provide compelling evidence that compounds 27 and 29 inhibit DENV replication in cells by binding to the N-pocket in the DENV polymerase.

Impact of resistance mutations on DENV NS5 polymerase activities and compound inhibition

To better understand the molecular mechanism of resistance caused by amino acid changes observed in the DENV RdRp, we generated RdRp mutants bearing these amino acid changes both in serotype DENV2 (L511V and E802D) and DENV4 (L512V and Q803N). Both the single and double mutant NS5 proteins have similar thermo-stability as WT protein and comparable dnI and elongation activities (Figs 6 and 7 in S1 Text). We then examined the impact of these mutations on the inhibitory capabilities of compounds 27 and 29 (Table 7). Both compounds were significantly less active against mutant enzymes than WT protein, in the dnI FAPA assay: IC50 value of 29 declined by 4–12 fold in DENV2 and DENV4, single mutants, whilst potency was further reduced in double mutant enzymes, by 52–133 fold lower than WT enzyme. For compound 27, IC50 values dropped by 5-88-fold in DENV2 single and double mutants. Changes in potency against DENV4 single and double mutants were even more severe: a complete loss of inhibitory activity (IC50 >20 μM) was observed. Furthermore, these compounds were less effective in stabilizing the mutant enzymes compared to the corresponding WT proteins (Fig 7 in S1 Text). Taken together, both in vitro enzyme profiling and thermo-denaturation studies strongly corroborate the resistant replicon phenotype obtained with 29.

Table 7. Inhibitory profiles of N-pocket compounds in DENV polymerase with resistant phenotype amino acid changes.

Impact of resistance mutations on DENV replication and compound inhibition

To evaluate the impact of L511V and E802D mutations on DENV replication, we introduced single (L511V or E802D) and double (L511V/E802D) amino acid changes into the DENV2 (strain NGC) replicon and its infectious full length virus genome. After electroporation into BHK-21 cells, replications of replicons (measured by renilla luciferase activity) or virus (measured by plaque assays) in the absence of compound, were monitored for 4 days (Fig 6; Table A in S1 Text). Electroporated cells harboring WT and mutant replicons showed similar multiplication rates and viability (Fig 6A). Compared to WT DENV2 replicon, all three mutant replicons replicated faster and generated higher levels of renilla luciferase signals (Fig 6B) as well as viral RNA (Fig 6C; Fig 8A in S1 Text) and NS5 levels (Fig 8A in S1 Text). Luciferase levels peaked at day 1 for mutants L511V and L511V/E802D, and at day 2 for WT and mutant E802D.

Fig 6. Growth kinetic profiles of DENV2 and its sub-genomic replicons with resistant phenotype amino acid changes, in absence of compound.

In vitro transcribed WT and mutant DENV2 replicon RNA were electroporated in BHK-21 cells, after which cell viability (A) and cellular renilla luciferase levels (B) were measured over four days with the Cell-titer-Glo and renilla luciferase assay systems (Promega, USA), respectively and read with a Clarity luminescence microplate reader (BioTek, USA). (C) Intra-cellular levels of viral replicon RNA were extracted from electroporated in BHK-21 cells and measured by real-time PCR using primers for DENV2 NS5. In vitro transcribed WT and mutant DENV2 full length genomic RNA were electroporated in BHK-21 cells, after which culture supernatants were harvested over four days and the levels of secreted infectious virus particles were determined by plaque assay (D) or extracted for viral RNA and quantified by real-time PCR using primers for DENV2 NS5 (E). All data points were measured in duplicates.

Experiments conducted with infectious WT and mutant DENV2 showed a different profile. Viral titers increased steadily from days 1–4 post-electroporation, unlike replicon growth curves (Fig 6D and 6E; Table 2B in S1 Text). L511V mutant produced the least infectious virus particles, compared to the other three viruses. Immunofluorescence staining of intracellular viral RNA and NS5 also revealed highest NS5 and dsRNA levels in mutant L511V (Fig 8B in S1 Text). The reason for the difference between extra- and intra-cellular viral RNA levels of mutants L511V is unclear. It is possible that mutation of this residue may have different impact on the replicon and virus.

Next, we examined the inhibitory effects of compounds 27 and 29 on the DENV2 single and double mutant replicons and viruses (Table 8). EC50 value of 29 was reduced by 3-6-folds in single and double mutant DENV2 replicons, compared to WT replicon. Similarly, its potency was also reduced by 5-6-folds in virus mutants compared against WT virus. These data further verify that the anti-DENV properties of 29 function through binding to the N-pocket in NS5 polymerase in DENV-infected cells.

Table 8. Inhibitory profiles of N-pocket compounds in DENV replicons and virus with resistant phenotype amino acid changes.

Potency reduction of compound 27 was less pronounced. Its EC50 values were reduced by 2-4-folds in mutant DENV2 replicons and viruses. The observed weaker EC50 shifts for 27 are puzzling as its binding mode is similar to 29 and involves non-covalent interaction of the thiophene ring with L511 and H-bond formation between the propargyl alcohol and E802D (Fig 3). Additional 27-resistant DENV2 EGFP-replicons were raised and studied. EC50 values of compounds 27 and 29 shifted by 17- and 10-folds, respectively, in these cells, compared to control cells raised in DMSO. Full replicon genome sequence analyses revealed secondary mutations present in NS5 methyl-transferase and NS4B in the 27-resistant replicon cells. Further reverse genetics on DENV2 with these amino acids are ongoing to better understand their roles in overcoming 27-mediated DENV2 growth inhibition.


In this report, we characterized a novel allosteric pocket at the interface of the thumb and palm subdomains of DENV RdRp [21, 22]. This binding site, which we termed the “N pocket”, was found through a fragment-based screening approach, by X-ray crystallography, using the DENV3 apo-RdRp protein as a target [37]. It is located near the priming loop (aa782-809) of the enzyme and is lined by residues highly conserved across DENV1-4, as well as in other flaviviruses including ZIKV (Fig 3G). Alanine substitutions, demonstrated that several N-pocket residues are important for NS5 polymerase de novo initiation activity and also for virus replication. Accordingly, N-pocket inhibitors generated by rational design potently inhibited DENV1-4 polymerase de novo initiation activities and virus replication in various cell types. They bind with strong affinity to recombinant apo-enzyme as well as FL NS5 from DENV replicon cell lysates.

Compound 29, one of the most potent compounds in the series, binds DENV RdRp with single-digit nano-molar affinity and stabilizes the RdRp melting temperature by 7.5–14 °C. It inhibits de novo initiation activity of DENV1-4 polymerases with IC50 values ranging from 13 to 38 nM. Alanine substitutions of N-pocket residues diminished the inhibitory properties of this class of compounds. Resistant DENV raised against compound 29, harbored amino acid mutations (L511V and E802D; DENV2 numbering) that mapped to the N-pocket. Correspondingly, these amino acid alterations reduced compound potencies in DENV cell-based and RdRp enzyme assays.

Residue L511 is conserved across DENV1-4, WNV and YFV. Residues 800 (H) and 802 (Q) are conserved across DENV-1, -3 and -4 but not in DENV2 (Fig 3G). In the laboratory adapted DENV2 strain, NGC, these residues are respectively, K and E, whilst in the DENV2 clinical isolate, MY097-10340, they are T and E. Crystal structure of DENV2-NGC RdRp bound with 27 showed that the OH- moiety of the propargyl alcohol arm, made similar hydrogen bonds with residues K800 (backbone N) and E802 (carboxylic acid side chain), as H800 and Q802 in the DENV3 RdRp-27 co-crystal structure. Residue T800 in DENV2, MY097-10340, would also be expected to form the same interaction as H800 or K800.

Kinetic studies showed that N pocket inhibitors have a mixed inhibition profile in the de novo initiation assay. Competitive experiments performed with GTP suggest differential inhibitory modes (non- and un-competitive) during initiation and elongation phases. Indeed, whilst compounds such as 27 and 29 have nano-molar IC50 values in the de novo initiation assay, their inhibitory potencies drop dramatically by 10–23 fold in the elongation assay (IC50 = 5.5 and 0.43 μM respectively). Given that both de novo initiation and elongation events occur simultaneously in DENV-infected cells, we speculate that N pocket inhibitors block the first activity better than the second, giving rise to the observed DENV cell-based EC50 values (example 29; EC50 = 2–14 μM). Order-of-reagent addition experiments further corroborate this hypothesis. Compound potencies are reduced only when the enzyme is occupied with newly synthesized duplex RNA, and not by single-stranded viral RNA. Presumably, retraction of the priming loop (aa782-809) from the active site during enzyme elongation alters the conformation of the N-pocket, leading to weaker binding affinities of the RdRp for the compounds.

DENV RdRp N-pocket compounds discovered here, share some common features with Site III non-nucleoside inhibitors described earlier for the HCV polymerase [29]. Site II (thumb 1), III (palm 1) and IV (palm 2) HCV RdRp inhibitors are de novo initiation inhibitors that lock the thumb subdomain in a conformation that prevents de novo initiation. Several such HCV inhibitors possess sub-micromolar EC50 values in HCV replicon cell-based assays and progressed into late phase clinical trials [44]. Of note, Dasabuvir (ABT 333), a Site III inhibitor, has recently been approved for HCV therapy in combination with NS3/4A protease and NS5 inhibitors ( HCV RdRp site III inhibitors bind at the interface of the thumb and palm subdomains, with one side comprising the “primer grip” and the opposite side formed by the β-hairpin loop from the thumb (equivalent to the priming loop in DENV RdRp). Inhibitor binding is promoted by interactions with both sides, in particular, with Y448 from the β-loop. The initiating nucleotide GTP, also binds to this site and forms key interactions with R386, S387 and R394 from HCV NS5B.

DENV RdRp N-pocket inhibitors also form several hydrogen bonds with residues from the priming loop that project from the thumb domain (aa794-802). Additionally, residues S710, R729 and R737 collectively form the mouth of the N-pocket and interact with the acyl-sulfonamide group from this class of inhibitors. This region of the binding pocket corresponds to the proposed i-1 site observed in other Flavivirus RdRps such as HCV, BVDV (discussed in [45]). The terminal aromatic rings of 27 and 29 protrude from the enzyme and are solvent-exposed. In the context of the replication complex, these compounds may differentially affect the interactions of NS5 with other viral or host proteins and further contribute to or contravene viral inhibition. Residues R729 and R737 in DENV RdRp are likely to play similar roles as R386 and R394 in HCV RdRp. They interact respectively with the γ- and β-phosphate of the GTP moiety bound in the DENV [21] and JEV RdRp active sites (corresponding to R734, R742, JEV numbering; [46]). Thus, N-pocket inhibitors could affect de novo initiation by interfering with the binding of the incoming +1 rNTP substrate.

Some differences with HCV NS5B are noteworthy: there is no equivalent of the HCV RdRp primer grip wall for DENV N-pocket. In addition, unlike HCV RdRp where the C-terminal loop penetrates the active site and participates in enzyme activity, the C-terminal end of flavivirus RdRp is disordered in most reported crystal structures. Interestingly, this segment was recently observed to interact with a neighbouring MTase domain in a DENV FL NS5 oligomeric structure [47]. We speculate that the absence of both regions in DENV RdRp active site, prevents formation of additional contacts with N-pocket inhibitors, and is the reason for the weaker binding affinities of N-pocket compounds, compared to HCV site III inhibitors. Design strategies that capture and order the C-terminal sequence of DENV RdRp or its G-loop [45], would likely further enhance inhibitor binding affinity and block de novo initiation.

Residue H798 in DENV priming loop was proposed to be the counterpart of Y448 in HCV RdRp and to be responsible for ATP-specific initiation [48]. Unfortunately, H798 is too distant to make contact with the acyl-sulfonamide moiety of the compounds and design strategies in this direction were not fruitful. However, given that the N-pocket is close to the enzyme active site, extensions of inhibitor towards the GDD motif may strengthen the compound affinity. High clearance was observed for acyl-sulfonamide propargyl alcohol compounds in vivo which rendered them unsuitable for mouse efficacy studies. Both the thiophene ring and the primary propargyl alcohol have potential metabolic liabilities in vivo. To develop N-pocket inhibitors with better pharmaco-kinetic properties, both groups would need to be replaced with more stable moieties, whilst retaining key hydrogen bond interactions, with residues such as 800 and 802.

Finally, compounds 27 and 29 were inactive when tested on the WNV replicon cell-based assay (Fig 9 in S1 Text). Previous comparisons revealed that the WNV RdRp priming loop is closer to the i-1 site, and prevents formation of a similar N-pocket [45]. In addition, whilst DENV N-pocket residues are mostly conserved across the flavivirus family, residues 799–802, which accommodate the propargyl alcohol arm, are more divergent (Fig 3G). Taken together, these may be the reasons for the lack of compound activity in WNV. Interestingly, residues 799–802 are more similar amongst JEV, MVEV WNV, YFV and ZIKV, compared to DENV1-4. In this light, it may not be plausible to develop pan-active N-pocket inhibitors that work on all flaviviruses. Rather, designing N-pocket inhibitors that specifically target different subgroups of the flavivirus family may be a more attainable goal.


Methods used in this study are briefly summarized below. Full descriptions are given in Supporting Information.

Cells, compounds, and antibodies

A549 cells (human alveolar epithelial cells; American Type Culture Collection (ATCC), USA) were maintained in Ham’s F-12K medium (LifeTech, USA) containing 10% fetal bovine serum (FBS), 1mM L-glutamine and 1% penicillin-streptomycin. BHK-21 cells (baby hamster kidney cells; ATCC, USA) were cultured in Dulbecco modified Eagle medium (DMEM; LifeTech, USA) supplemented with 10% FBS, 1 mM L-glutamine and 1% penicillin-streptomycin. C6/36 mosquito cells (ATCC, USA) were grown in RPMI 1640 medium containing 10% FBS, 1 mM L-glutamine and 1% penicillin-streptomycin. A549, BHK-21 and HuH7 (Japan Collection of Research Bioresources Cell Bank, Japan) cells containing a DENV2 (New Guinea C) renilla luciferase or EGFP sub-genomic replicon were maintained in F-12 and DMEM medium, respectively, containing 10% FBS, 1 mM L-glutamine 20 μg/ml puromycin, and 1% penicillin-streptomycin [40]. Huh-7.5 cells containing a firefly luciferase sub-genomic replicon of hepatitis C virus (HCV) genotype 1b were licensed from Apath LLC (St. Louis, MO, USA; 42) and were maintained in DMEM containing 10% FBS, 1 mM L-glutamine, 0.25 mg/ml Geneticin, and 1% penicillin-streptomycin. A549, BHK-21, DENV2 replicon, and HCV replicon cell lines were incubated at 37°C. C6/36 cells were cultured at 28°C. All compounds were synthesized in-house. DENV-specific mouse monoclonal antibody 4G2 against the DENV envelope (E) protein was prepared from a hybridoma cell line purchased from the ATCC (USA) and rabbit poly-clonal antibody against DENV2 NS5 was purchased from GeneTex (USA). Synthesis of N-pocket inhibitors are described in [38].

Cloning, expression and activity tests of DENV1-4 WT and mutant FL NS5 proteins

Site-directed alanine mutations of DENV4 FL NS5 cDNA were performed using pET28-D4-MY01-22713 NS5FL [23] as a template, according to the manufacturer’s protocol (Stratagene, USA). Protein expressions of DENV1-4 FL NS5 and their stability analyses by thermo-fluorescence were performed as described previously [23]. DENV de novo initiation and elongation FAPA assays were earlier described [25].

Crystallization and X-ray structure determination

DENV3 RdRp protein expression and crystallization was as described previously [22]. Briefly, DENV3 RdRp at 12 mg/ml was mixed with 1 mM compound 27 or 29 (prepared from a 10 mM DMSO stock to give a final concentration of 10% DMSO) prior to setting up hanging-drop vapor-diffusion crystallization trials in 0.1 M Tris/HCl, pH 8.0 and 25% PEG 500 MME. DENV2 RdRp (Strain NGC, aa 266–900) protein expression was as described previously (23). Protein crystallization was performed at 8 mg/ml in a sitting-drop vapor-diffusion setup with a well solution of 0.1 M MES pH 7.0, 0.35 mM MgCl2 and 16% PEG 4000 with a drop ratio of 2:1 (protein:well). Crystals appeared in one day and were transferred to the well solution supplemented with 10 mM compound 27 (prepared from a 100 mM DMSO stock to obtain a final concentration of 10% DMSO) for overnight incubation. For cryo-protection, crystals were transferred to the crystallization solution supplemented with 10% glycerol and 10% compound/DMSO and cooled in liquid nitrogen. Diffraction data were integrated using autoPROC (DENV2) or XDS (DENV3) and scaled using SCALA or AIMLESS, both part of the CCP4 suite [49]. The structures were directly refined using BUSTER, part of the global phasing suite.

Surface plasmon resonance binding assay

Biotinylated DENV3 and DENV4 RdRp were captured on flow cells 2 and 4 respectively in 50 mM Tris/HCl, pH 7.5, 200 mM NaCl, 2 mM DTT, 0.05% Tween 20, and 3% DMSO at 4°C. Flow cell 1 and 3 were left blank to serve as a reference [37]. Compounds were tested in a 7-point 2-fold serial dilution, from 2.5 μM and a zero-concentration sample was subtracted from each run. Compounds were injected at a flow rate of 30 μL/min, with 45 s contact time and 600 s dissociation, starting from the DMSO control and finishing with the highest concentration. The experiments were performed using a Biacore T200 instrument and the data were analyzed using Biacore T200 Evaluation software, version 2.0.

Compound testing with DENV dnI FAPA assays

DENV1-4 FL NS5 dnI assays were performed as described previously [39]. Briefly, compounds from 0–20 or -100 μM concentrations are two-fold serially diluted into 384-well black opaque plates (Corning Costar), after which 100 nM DENV FL NS5 protein was added and the plates incubated at RT for 20 min. RNA and ATTO-CTP, ATP, GTP and UTP were then added and the plates incubated for another 120 min. Reactions were stopped with buffer containing 25 nM CIP, re- incubated at RT for 60 min and read on a Tecan Safire II microplate reader. For order-of-addition experiments, DENV4 FL NS5 was incubated for one hour at RT with RNA, ATP, and GTP or RNA, ATP, GTP and ATTO-CTP, followed by exposure to serially diluted compounds for 20 min at RT. The missing components (ATTO-CTP and UTP or UTP alone) were added and the reactions continued for 120 min after which STOP buffer was added as before. All datapoints were performed in duplicate wells. Each compound was tested at least twice.

Selection and sequencing of resistant virus

BHK-21 DENV2 (strain New Guinea C) EGFP-replicon cells [40] resistant to compounds 27 and 29 were first obtained by serial passaging of the cells in 14 μM of 27 or 20 μM of 29 (1–2× EC90 values). Briefly, 1 X 105 cells were seeded over-night into 6-well plates, followed by addition of fresh media containing 2% FCS and compounds. Media was changed every 2–3 day. After 5 weeks, concentration of 29 was increased to 25 μM. Individual colonies or mixed populations of resistant cells were isolated, expanded and total cellular RNA extracted. Alternatively, native replicon cells were incubated with media containing 1.5 μM of 27 (0.5X EC50 value) and after 3 days, fresh media with 2-fold increase in compound concentration was added. The process was repeated until cells were exposed to 28 μM 27, after which total cellular RNA was extracted. Viral RNA was extracted by using QIAamp viral RNA minikit (Qiagen) and NS5 cDNA was amplified by SuperScript One-Step reverse transcription (RT)-PCR with Platinum Taq (Invitrogen) and subjected to DNA sequencing. Control cells were passaged in the presence of 0.5% DMSO.

Generation of DENV4 NS5 mutant replicons

Mutations in the DENV4 NS5 (GenBank accession number AF326825) sequence were engineered into the subclone, pACYC-DENV4-F shuttle, using the QuikChange II XL site-directed mutagenesis kit according to the manufacturer’s protocol (Stratagene). This plasmid harbours nucleotides 7564–10653 (from NS3-3’UTR) from the DENV4, MY01-22713 strain, linked at the 3’end to the Hepatitis D virus ribozyme (HDVr) sequence. Following sequence verification, the plasmids were digested with NotI and KpnI and inserted with a PCR product comprising the sequence comprising nucleotides 1–7563 downstream of the T7 promoter in which the region from nucleotides 217–2291 in this cDNA has been replaced by renilla luciferase and foot-and-mouth disease virus 2A protease cDNAs [50].

Construction of mutant DENV2 replicons and full-length infectious clone

DENV2 (strain New Guinea C, NGC) replicons or full-length cDNA clones with NS5 mutations were constructed with a pACYC-NGC-RLuc replicon or pACYC-NGC FL, respectively and a TA-NGC (shuttle E) vector as previously described [50]. The pACYC-NGC FL plasmid contains the T7 promoter, the DENV2 NGC genome, and HDVr. The pACYC- NGC-RLuc replicon plasmid contains the same cDNA as pACYC-NGC FL except that cDNAs encoding structural proteins were replaced by renilla luciferase cDNA [40]. The shuttle E vector contains nucleotides 5427 to 10955 (from NS3 to 3’UTR and HDVr sequence). All NS5 mutations were engineered into the shuttle E vector, using QuikChange II XL site-directed mutagenesis kit (Stratagene) according to the manufacturer’s protocol. The mutants were cloned into pACYC-NGC replicon or FL plasmid at BspEI and MluI restriction sites. All constructs were verified by DNA sequencing.

Compound testing in DENV replicons and infectious virus and HCV replicon

A549, BHK-21 and Huh7 cells bearing stable DENV2 sub-genomic replicon [40] or transiently electroporated DENV2-NGC replicon or infectious virus cDNAs were seeded into 384-well microplate (3,000 cells per well). After over-night incubation at 37°C with 5% CO2, the cells were treated with 2-fold serially diluted compounds, starting from 20 or 50 μM. At 48 hr of post-incubation, renilla luciferase activities were measured with the ViviRen live-cell substrate (Promega, USA) according to the manufacturer’s protocol. CellTiter-Glo reagent (Promega, USA) was then added to determine cytotoxic effects of compounds. For the HCV replicon assay, Huh-7.5 cells harboring the HCV replicon [43] were seeded into a 96-well microplate (20,000 cells per well). At 48 hr after compound treatment, cells were assayed for firefly luciferase activity by using a Bright-Glo luciferase assay (Promega, USA). NITD-008, a nucleoside inhibitor of DENV and HCV was added as a control [33]. Compounds were tested up to 25 μM in HCV replicon cells due to limits in DMSO tolerability of these cells, and up to 50 μM in other cell types, based on compound solubility.

Supporting Information

S1 Text.

Fig 1A. Representative IC50 curves for N-pocket inhibitors tested in DENV4 FL NS5 de novo initiation FAPA assay [3]. Briefly, compounds (10-point, 3-fold serially diluted compounds from 0–20 or 100 μM) were incubated at RT for 20 min with enzyme alone, in 384-well plate opaque plates, after which reactions were started with addition of ssRNA and nucleotide substrate components, and allowed to proceed for 2 hr. Reactions were stopped by addition of 10 μl of 2.5X STOP buffer with 25 nM CIP, re- incubated at RT for 60 min and read on a Tecan Safire II microplate reader (excitationmax and emissionmax wavelengths 422 nm and 566 nm). Data was fitted to the four parameter logistic equation and IC50 curves plotted using Graphpad® Prism software. Table contains average IC50 values and hill slopes obtained. All data points were measured in duplicates. Fig 1B. Representative EC50 and CC50 curves for N-pocket inhibitors tested in HuH-7 DENV-2 replicon cell-based assay [1]. Cells were seeded over-night in white opaque 384-well plates followed by incubation with increasing compound concentrations (10-point, 2-fold serially diluted compounds from 0–50 μM) for 48 hr, after which cellular renilla luciferase (EC50) or ATP (CC50) levels, measured as relative light units (RLU), were determined using ViviRen and Cell Titer-Glo (Promega) according to manufacturer’s protocol. All data points were measured in duplicates. Fig 2. Enzyme inhibition kinetics of N-pocket compounds against DENV polymerase. DENV4 FL NS5 dnI FAPA assays [5] were performed in increasing concentrations of N-pocket inhibitor, 15 or 29 or 3’dGTP (control) with 0–500 nM RNA or 0–50 μM GTP to determine mechanism of inhibition with respect to either suibstrates. Representative Michaelis-Menton plots were derived from non-linear regression curve fitting using Graphpad Prism software. Fig 3. Crystal structures of DENV3 FL NS5 were obtained by co-crystallization according to conditions from reference 7 as described in Supplementary Materials. (A) Overall view of the DENV3 FL NS5 structure displayed as ribbon with the methyltransferase domain in red, the linker region in orange, palm, thumb and fingers subdomains colored in olive, green and blue respectively. Both compounds 23 (magenta sticks) and 29 (yellow sticks) are overlaid in the polymerase domain. Magnified views of compound 29 (B) and 27 (C) with Fo-Fc contoured at 4 σ where each compound was omitted from the phase calculation. (D) Superimposition of the RdRp domain from FL NS5 (green ribbon) and RdRp (pink ribbon) with bound compounds 29 and 23 in sticks showing the absence of conformational changes. (E) Superimposition of compound 29 bound to FL NS5 structure (magenta sticks) and bound to RdRp structure (pink sticks) and compound 23 (panel F) bound to FL NS5 (grey sticks) and bound to RdRp (orange sticks). The compound conformations are closely superimposable. PDB codes for the FL NS5 structures with compounds 27 and 29 are 5JJS and 5JJR, respectively. Fig 4. Phylogenetic tree representing relatedness of N-pocket amino acid residues from different members of the Flavivirus family, derived from Clustal Omega program [8]. Fig 5. Effects of N-pocket compounds on DENV polymerase thermo-stability. Melting temperature (Tm) was assessed by thermo-denaturation in presence of the SYPRO Orange dye as described in Materials and Methods. (A-F) Representative melting curves of DENV4 RdRp domain (aa 266–900; A-C) and FL NS5 (D-F) in presence of 50 μM N-pocket inhibitors or 5% DMSO control. (G) Cellular thermal shifts assays [9] were performed with BHK-21 DENV2-NGC replicon cell lysates and 40 mM of 27 or 29. Briefly, lysates were incubated with compounds or 5% DMSO for 1 hr at 4 °C, followed by heating at 30–70 °C. Samples were spun and the supernatants loaded onto 12% SDS-PAGE gels, followed by gel electrophoresis and western blotting with anti-DENV2 NS5 antibody (GeneTex, USA). Table shows the changes in protein melting temperatures in presence of compounds compared to controls treated with DMSO. Fig 6. Activity profiles of DENV polymerase bearing resistant phenotype amino acid changes. Recombinant DENV2 (A, C) and DENV4 (B, D) FL NS5 proteins bearing single or double amino acid changes in the N-pocket were tested in de novo initiation (A, B) and elongation (C, D) FAPA assays and compared against activities of WT DENV2 or DENV4 FL NS5 proteins. Reactions were conducted over 2 hr at RT and from average relative fluorescence units (RFU) obtained from one experiment. All data points were measured in triplicate. Fig 7. Effects of compounds on DENV polymerase thermo-stability. Melting temperature (Tm) was assessed by thermo-denaturation in presence of the SYPRO Orange dye as described in Materials and Methods. (A-D) Representative melting curves of in vitro expressed recombinant DENV2 FL NS5 WT or mutant proteins in presence of 50 μM compound or 5% DMSO control. Table shows the melting temperatures of DENV-2 and -4 FL NS5 WT and mutant proteins as well as the changes in their melting temperatures in presence of compounds compared to controls treated with 5% DMSO. Fig 8. Analysis of viral and NS5 protein expressions from DENV WT and mutant replicons and virus. Immuno-fluorescence stainings for DENV dsRNA and NS5 protein were performed on BHK-21 cells at days 1–4 (D1-4) after electroporation of DENV-2 WT and mutant (A) replicon or (B) full length viral IVT RNA. Cells were fixed and the stated time-points and probed with mouse monoclonal anti-dsRNA (red; Scicons, USA) and rabbit polyclonal anti-NS5 (green; GeneTex, USA) primary antibodies, and goat anti-mouse-IgG- Alexa Fluor568 and goat anti-rabbit-IgG-FITC secondary antibodies (Invitrogen, USA). Nuclear DNA was stained with DAPI (blue; Thermofisher, USA). Fig 9. WNV (New York strain 3356) replicon cDNA was electroporated in BHK-21 cells, after which cells were seeded into 96-well plates and treated with compounds, 26i, 27, 29 and 29i (10-point, 3-fold serially diluted compounds from 0–50 μM), for 2 days. EC50 values from replicon cells were determined by measuring cellular renilla luciferase levels. All data points were measured in duplicates. Table 1. Data collection and refinement statistics of DENV3 FL NS5 co-crystals. Table 2. Analysis of DENV2 (strain NGC) WT and mutant replicons and virus replication.



We thank Thierry Diagana, David Beer, Paul Smith and Francesca Blasco for support and useful discussions, Nicole Tay, Ka Yan Chung, Katherine Chan, Lim Chin Chin, Hao Ying Xu, Agatha Susila and Alexander Theodore Chao, for technical support, and colleagues at Novartis Biomedical Research Institute, Emeryville, CA, USA, for compound testing in human rhinovirus cell-based assays. We thank Shamala Devi for providing the clinical isolates of the four serotypes of dengue virus. JL and AES were supported by National Medical Research Council Grant CBRG14May051 (to JL).

Author Contributions

  1. Conceived and designed the experiments: SPL CGN JL TB SN PYS FY.
  2. Performed the experiments: SPL CGN CCS TSS AES GKYC JL RA SN HD FY.
  3. Analyzed the data: SPL CGN CCS TSS AES JL RA TB SN UM KFW PYS FY.
  4. Contributed reagents/materials/analysis tools: SPL CGN CCS TSS AES JL RA TB SN XX KFW FY.
  5. Wrote the paper: SPL JL.


  1. 1. Muso D, Gubler DJ (2016) Zika virus. Clin Microbiol Rev 29: 487–524. pmid:27029595
  2. 2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. (2013) The global distribution and burden of dengue. Nature 496: 504–507. pmid:23563266
  3. 3. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al.; CYD14 Study Group (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 1358–1365. pmid:25018116
  4. 4. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559–67. pmid:22975340
  5. 5. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, et al. (2013) Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100: 500–519. pmid:24076358
  6. 6. Mackenzie J (2005) Wrapping things up about virus RNA replication. Traffic 6: 967–977. pmid:16190978
  7. 7. Miller S, Krijnse-Locker J (2008) Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol 6: 363–374. pmid:18414501
  8. 8. Salonen A, Ahola T, Kaariainen L (2005) Viral RNA replication in association with cellular membranes. Curr Top Microbiol Immunol 285: 139–173. pmid:15609503
  9. 9. Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B (2002) An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J 21: 2757–2768. pmid:12032088
  10. 10. Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, Dong H, et al. (2006) West nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. J. Virol 80: 8362–8370. pmid:16912287
  11. 11. Dong H, Ren S, Zhang B, Zhou Y, Puig-Basagoiti F, Li H, et al. (2008) West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J Virol 82: 4295–4307. pmid:18305027
  12. 12. Chung KY, Dong H, Chao AT, Shi PY, Lescar J, Lim SP. (2010) Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2'-O methyltransferase activity in dengue virus. Virology 402: 52–60. pmid:20350738
  13. 13. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, et al (2010) 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468: 452–6.
  14. 14. Dong H, Chang DC, Hua MH, Lim SP, Chionh YH, Hia F, et al. (2012) 2'-O methylation of internal adenosine by flavivirus NS5 methyltransferase. PLoS Pathog 8: e1002642. pmid:22496660
  15. 15. Zhao Y, Soh TS, Lim SP, Chung KY, Swaminathan K, Vasudevan SG, et al. (2015) Molecular basis for specific viral RNA recognition and 2'-O-ribose methylation by the dengue virus nonstructural protein 5 (NS5). Proc Natl Acad Sci USA 112: 14834–14839. pmid:26578813
  16. 16. Issur M, Geiss BJ, Bougie I, Picard-Jean F, Despins S, Mayette J, et al. (2009) The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 15: 2340–2350. pmid:19850911
  17. 17. Bollati M, Milani M, Mastrangelo E, Ricagno S, Tedeschi G, Nonnis S, et al. (2009) Recognition of RNA cap in the Wesselsbron virus NS5 methyltransferase domain: implications for RNA-capping mechanisms in Flavivirus. J Mol Biol 385(1): 140–152. pmid:18976670
  18. 18. Ackermann M, Padmanabhan R, (2001) De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J. Biol. Chem. 276: 39926–39937. pmid:11546770
  19. 19. Nomaguchi M, Teramoto T, Yu L, Markoff L, Padmanabhan R, (2004) Requirements for West Nile virus (-)- and (+)-strand subgenomic RNA synthesis in vitro by the viral RNA dependent RNA polymerase expressed in Escherichia coli. J. Biol, Chem. 279: 12141–12151.
  20. 20. Malet H, Egloff MP, Selisko B, Butcher RE, Wright PJ, Roberts M, et al. (2007) Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J Biol Chem 282: 10678–10689. pmid:17287213
  21. 21. Yap TL, Xu T, Chen YL, Malet H, Egloff MP, Canard B, et al. (2007) Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J Virol 81: 4753–4765. pmid:17301146
  22. 22. Noble CG, Lim SP, Chen YL, Liew CW, Yap L, Lescar J, et al. (2013) Conformational flexibility of the Dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor. J Virol 87: 5291–5295. pmid:23408636
  23. 23. Lim SP, Koh JH, Seh CC, Liew CW, Davidson AD, Chua LS, et al. (2013) A crystal structure of the dengue virus non-structural protein 5 (NS5) polymerase delineates interdomain amino acid residues that enhance its thermo-stability and de novo initiation activities. J Biol Chem 288: 31105–31114. pmid:24025331
  24. 24. Potisopon S, Priet S, Collet A, Decroly E, Canard B, Selisko B, et al. (2014) The methyltransferase domain of dengue virus protein NS5 ensures efficient RNA synthesis initiation and elongation by the polymerase domain. Nucleic Acids Res 42: 11642–11656. pmid:25209234
  25. 25. Zhao Y, Soh S, Zheng J, Chan KWK, Phoo WW, Lee CC, et al. (2015) A crystal structure of the dengue virus NS5 protein reveals a novel inter-domain interface essential for protein flexibility and virus replication. PLOS Pathogens 11(3):e1004682. pmid:25775415
  26. 26. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A (2009) NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 83: 5408–5418. pmid:19279106
  27. 27. Hannemann H, Sung PY, Chiu HC, Yousuf A, Bird J, Lim SP, et al. (2013) Serotype-specific differences in dengue virus non-structural protein 5 nuclear localization. J Biol Chem 288: 22621–22635. pmid:23770669
  28. 28. Sousa R (1996) Structural and mechanistic relationships between nucleic acid polymerases. Trends Biochem Sci 21: 186–190. pmid:8871404
  29. 29. Caillet-Saguy C, Lim SP, Shi P-Y, Lescar J, Bressanelli S (2014) Polymerases of hepatitis C viruses and flaviviruses: Structural and mechanistic insights and drug development. Antiviral Res 105:8–16. pmid:24561230
  30. 30. Keller TH, Chen YL, Knox JE, Lim SP, Ma NL, Patel SJ, et al. (2006) Finding new medicines for flaviviral targets. Novartis Found Symp 277: 102–114; discussion 114–109; 251–103. pmid:17319157
  31. 31. Noble CG, Shi PY (2012) Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res 96: 115–126. pmid:22995600
  32. 32. Lim SP, Noble CG, Shi PY (2015) The dengue virus NS5 protein as a target for drug discovery. Anti-viral Res 119: 57–67.
  33. 33. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, et al. (2009a) An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 106: 20435–20439.
  34. 34. Yin Z, Chen YL, Kondreddi RR, Chan WL, Wang G, Ng RH, et al (2009b) N-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase. J Med Chem 52: 7934–7937.
  35. 35. Niyomrattanakit P, Chen YL, Dong H, Yin Z, Qing M, Glickman JF,et al. (2010). Inhibition of dengue virus polymerase by blocking of the RNA tunnel. J Virol 84: 5678–5686. pmid:20237086
  36. 36. Smith TM, Lim SP, Yue K, Busby SA, Arora R, Seh CC, et al. (2014) Identifying Initiation and Elongation Inhibitors of Dengue Virus RNA Polymerase in a High-Throughput Lead-Finding Campaign. J Biomol Screen 20: 153–163. pmid:25252731
  37. 37. Noble CG, Lim SP, Arora R, Yokokawa F, Nilar N, Seh CC, et al. (2016) A conserved pocket in the dengue virus polymerase identified through fragment-based screening. J. Biol Chem 291: 8541–8548. pmid:26872970
  38. 38. Yokokawa F, Shahul N, Noble CG, Lim SP, Rao R, Tania S, et al. (2016) Discovery of Potent Non-Nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase From a Fragment Hit Using Structure-Based Drug Design. J. Med Chem 59: 3935–3952 pmid:26984786
  39. 39. Niyomrattanakit P, Wan KF, Chung KY, Abas SN, Seh CC, Dong H, et al. (2015) Stabilization of dengue virus polymerase in de novo initiation assay provides advantages for compound screening. Antiviral Res 119: 36–46. pmid:25896272
  40. 40. Ng C, Gu F, Phong WY, Chen Y, Lim SP, Davidson A, et al (2007) Construction and Characterization of a Stable Subgenomic Dengue virus type 2 Replicon System for antiviral compound and siRNA screening. Antiviral Res 76: 222–231. pmid:17662475
  41. 41. Molina MD, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, Sreekumar L, Cao Y, Nordlund P (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341: 84–87. pmid:23828940
  42. 42. Sievers F, Wilm A, Dineen DG, Gibson TJ, Karplus K, Li W, et al. (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology 7: 539. pmid:21988835
  43. 43. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972–1974. pmid:11110665
  44. 44. Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS (2012) Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem 55: 2481–2531. pmid:22185586
  45. 45. Malet H, Massé N, Selisko B, Romette JL, Alvarez K, Guillemot JC et al. (2008) The flavivirus polymerase as a target for drug discovery. Antiviral Res. 80: 23–35. pmid:18611413
  46. 46. Surana P, Satchidanandam V, Nair DT (2014) RNA-dependent RNA polymerase of Japanese encephalitis virus binds the initiator nucleotide GTP to form a mechanistically important pre-initiation state. Nucleic Acids Res 42: 2758–2773. pmid:24293643
  47. 47. Klema VJ, Ye M, Hindupur A, Teramoto T, Gottipati K, Padmanabhan R, et al. (2016) PLoS Pathog. 12(2):e1005451. pmid:26895240
  48. 48. Selisko B, Potisopon S, Agred R, Priet S, Varlet I, Thillier Y, et al. (2012) Molecular basis for nucleotide conservation at the ends of the dengue virus genome. PLoS Pathog 8: e1002912. pmid:23028313
  49. 49. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235–242. pmid:21460441
  50. 50. Wang QY, Dong H, Zou B, Karuna R, Wan KF, Zou J, et al. (2015) Discovery of Dengue Virus NS4B Inhibitors. J Virol 89: 8233–8244. pmid:26018165